Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

SYNBIOTIC SE: subsidiary Hempro International applies for preliminary insolvency proceedings

Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » More on finanzen.net
SynBiotic share plunges almost 20% after US cannabis reclassification

The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » More on finanzen.net
Synbiotic shares more than double since Friday after anchor investor steps in

Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » More on de.investing.com
SYNBIOTIC SE decides on capital increase of up to 200,000 new shares

SYNBIOTIC SE is using authorized capital to increase share capital by up to EUR 200,000 through the issuance of up to 200,000 new registered shares at a placement price of EUR 1.70 per share, with statutory subscription rights excluded. The new shares will be entitled to profits from 1 January 2024; Small & Mid Cap Investmentbank AG has been appointed to handle the placement. The net proceeds from the issuance are intended to support the company's growth. » More on finanzen.net
SYNBIOTIC: subsidiary Bushdoctor files for insolvency proceedings

Bushdoctor GmbH has applied to the Landesgericht Wiener Neustadt to open insolvency proceedings. As part of the restructuring, SYNBIOTIC suspended financial support for the subsidiary, which led to the filing. The announcement confirms that the operational development of the subsidiaries is being reviewed as part of the group restructuring. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, SynBiotic has already paid €0.30 in dividends. The last payout was in July 2022.

Financials

In the last year, SynBiotic had revenue of €14.31m and net profit of -€9.72m

(EUR)	2024	YoY
Revenue	14.31m	270.47%
Gross profit	4.86m	222.69%
Net profit	-9.72m	8.60%
EBITDA	-2.03m	71.55%

Fundamentals

Metric	Value
Market capitalization	€1.04m
Number of shares	7.99m
52-week high/low	€3.85 - €0.10
Dividends	No
Beta	0.68
P/E ratio	-0.08
PEG ratio	0.00
P/B ratio	0.03
P/S ratio	0.07

Company profile

SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.